Latest News-Ascletis Pharma Inc. Mediaroom_Page

Ascletis Announces First Patient Dosed in the U.S. Phase I Clinical Trial of Oral PD-L1 Small Molecule Inhibitor Prodrug ASC61 for Treatment of Advanced Solid Tumors

--ASC61 is an in-house developed oral PD-L1 small molecule inhibitor prodrug that showed significan...

2022-08-08 08:10 3702

Ascletis Announces IND Filing of Oral RdRp Inhibitor ASC10 for COVID-19 Accepted by China NMPA

HANGZHOU, China and SHAOXING, China, Aug. 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,...

2022-08-04 08:10 4293

Ascletis Announces FDA Clearance of Oral RdRp Inhibitor ASC10 to Conduct a Randomized, Placebo Controlled Phase Ib Study in Mild-to-Moderate COVID-19 Patients

-- ASC10 is an oral double prodrug that is rapidly and completely converted in vivo into the active...

2022-08-03 16:50 3631

Ascletis Announces U.S. IND Filing of Oral RdRp Inhibitor Drug Candidate ASC10 for COVID-19

-- ASC10 is an oral small molecule drug candidate, which is in-house discovered and developed, and ...

2022-07-06 08:10 4956

Shanghai Public Health Clinical Center Completed the First Patient Dosing in Clinical Study of PD-L1 Antibody ASC22 in Combination with Chidamide for Functional Cure of HIV Infection

HANGZHOU and SHAOXING, China, July 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...

2022-07-04 08:10 3771

Ascletis Announced First Subject Dosed in the Phase II Clinical Trial of ASC22 (Envafolimab) for Immune Restoration/ Functional Cure of HIV-1 Infection

-- The Phase II clinical study in China is currently expected to be completed in early 2023 with an...

2022-06-28 18:11 3599

Ascletis' Subcutaneous PD-L1 Antibody ASC22 Demonstrated Potential of Functional Cure of Chronic Hepatitis B as 42.9% of Patients with Baseline HBsAg≤100 IU/mL Obtained Sustained HBsAg Loss

--Ascletis presented Phase IIb clinical trial results of subcutaneous PD-L1 antibody ASC22 for func...

2022-06-27 08:11 4010

Ascletis Announces Oral Presentation on Updates from Phase IIb Clinical Trial of ASC22, a Subcutaneous PD-L1 Antibody for Functional Cure of Chronic Hepatitis B at EASL ILC 2022

- The updates of ASC22 Phase IIb study will be presented at the oral session during the Internation...

2022-06-16 08:10 3839

Ascletis Announces Appointment of Mr. John P. Gargiulo, Former North America President and CEO of Daiichi Sankyo, as Chief Business Officer

HANGZHOU, China and SHAOXING, China, June 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-06-13 08:00 3603

Gannex Announces U.S. FDA Clearance of Clinical Trial on FXR Agonist ASC42 for Treatment of Primary Biliary Cholangitis

-- ASC42 has completed Phase I trials in the U.S. and China. This approval from U.S. FDA enables Ga...

2022-06-08 20:10 3948

Ascletis (1672.HK) Included in MSCI China Small Cap Index

HANGZHOU and SHAOXING, China, May 16, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascle...

2022-05-16 20:17 5553

Ascletis Announces U.S. IND Approval of ASC22 (Envafolimab) for Immune Restoration/Functional Cure of HIV-1 Infected Patients

HANGZHOU, China and SHAOXING, China, May 11, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672,...

2022-05-11 08:40 4220

Ascletis Announces 3CLpro Inhibitor ASC11 Demonstrated Potential to be Effective Treatment for COVID-19

- In antiviral cellular assays, antiviral potency (EC90) of ASC11 is 31-fold of that of Nirmatrelvi...

2022-04-19 16:50 3852

Ascletis Announces Cooperation with China Meheco International Co., Ltd. in Distribution of Its Ritonavir Tablets in Chinese Mainland

HANGZHOU, China and SHAOXING, China, April 13, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 167...

2022-04-13 21:00 4186

Gannex Announces First Patient Dosed in Phase II Clinical Trial of ASC42, an FXR Agonist, for Primary Biliary Cholangitis

-- Gannex is expected to complete the Phase II trial in 100 patients by the end of 2022. -- Gannex...

2022-04-10 18:20 2611

Ascletis Announces China IND Approval of Its Second FASN Inhibitor ASC60 for Treatment of Advanced Solid Tumors

HANGZHOU, China and SHAOXING, China, April 6, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX code:...

2022-04-06 17:10 4872

Ascletis Announces Completion of First Sale of Its Ritonavir Tablets in Zhejiang Province

HANGZHOU, China and SHAOXING, China, April 4, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672...

2022-04-04 17:10 3985

Ascletis Announces Submission of Marketing Authorization Application for Ritonavir in Hong Kong

HANGZHOU and SHAOXING, China, April 3, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672) today...

2022-04-03 18:20 4978

Ascletis Announces Completion of Patient Enrollment in Phase II Clinical Trial of ASC42, an In-House Developed, Best-in-Class FXR Agonist for Chronic Hepatitis B Indication

--Compared to the placebo cohort, both 10 mg and 15 mg ASC42 cohorts are safe and well tolerated to...

2022-03-30 18:26 3319

Ascletis Announces the Latest Results of the Preclinical Studies of Two Novel Anti-Cancer Drug Candidates, ASC61 and ASC60, to be presented at AACR Annual Meeting 2022

HANGZHOU, China and SHAOXING, China, March 27, 2022 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX:1672...

2022-03-27 18:30 4957